Clinical efficacy and molecular mechanism of nourishing shen and supplementing marrow principle in treating β-thalassemia

Wu Zhi-kui; Fang Su-ping; Zhang Xin-hua; Cai Hui-guo; Wang Lei; Yi Jie; Chai Li-min; Lu Xin-xia; Chen Yu-ying; Huang You-wen; Wang Rong-xin; Chen Pei-zhen

doi:10.1007/BF02838606

Your Location：

Home >

Browse articles >

Clinical efficacy and molecular mechanism of nourishing shen and supplementing marrow principle in treating β-thalassemia

Updated：2021-08-27

- Clinical efficacy and molecular mechanism of nourishing shen and supplementing marrow principle in treating β-thalassemia
- Chinese Journal of Integrative Medicine Vol. 9, Issue 4, Pages: 248-253(2003)
- Affiliations：
  
  1. Department of Molecular-Biology, Guang’anmen Hospital, China Academy of Traditional Chinese Medicine,Beijing
  2. Institute of Hematology, Chinese Academy of Medical Sciences,China
  3. The Hospital of PLA,China,303
- Author bio：
- Funds：
  
  This item was supported by National Funds of Natural Sciences (No. 30171199) and Natural Science Foundation of Guangxi Autonomous Region (No. 014402C)
- DOI：10.1007/BF02838606
  CLC：
- Published：2003，
Scan for full text
Zhi-kui, W., Su-ping, F., Xin-hua, Z. et al. Clinical efficacy and molecular mechanism of nourishing shen and supplementing marrow principle in treating β-thalassemia., Chin. J. Integr. Med. 9, 248–253 (2003). https://doi.org/10.1007/BF02838606

Wu Zhi-kui, Fang Su-ping, Zhang Xin-hua, et al. Clinical efficacy and molecular mechanism of nourishing shen and supplementing marrow principle in treating β-thalassemia. [J]. Chinese Journal of Integrative Medicine 9(4):248-253(2003)
Zhi-kui, W., Su-ping, F., Xin-hua, Z. et al. Clinical efficacy and molecular mechanism of nourishing shen and supplementing marrow principle in treating β-thalassemia., Chin. J. Integr. Med. 9, 248–253 (2003). https://doi.org/10.1007/BF02838606 DOI：

Wu Zhi-kui, Fang Su-ping, Zhang Xin-hua, et al. Clinical efficacy and molecular mechanism of nourishing shen and supplementing marrow principle in treating β-thalassemia. [J]. Chinese Journal of Integrative Medicine 9(4):248-253(2003) DOI： 10.1007/BF02838606.

摘要

Objective: To explore the possibility of using traditional Chinese medicine (TCM) in treating β-thalassemia

its clinical effect and molecular mechanism of the action.Methods: According to the TCM theory of “Shen producing marrow”

the composite recipe

Yisui Shenxueling Granule (YSSXL)

consisting of Chinese drugs for nourishing Shen and supplementing marrow (NS & SM) was given orally to 78 patients with β-thalassemia (49 of the severe type and 29 of moderate type)

3 times a day

10 g each time (for children

the dose would be reduced properly)

with 3 months as one therapeutic course

and no blood transfusion used in the course. The clinical therapeutic efficacy and hematologic parameters in patients were observed

and systemic gene analysis was conducted with PAGE

PCR

PCR-SSCP

RT-PCR and DNA sequences analysis and mRNA detection

in order to study the molecular mechanism from the relationships between genetic mutation and clinical efficacy

gene expression and its regulation.Results: YSSXL showed obvious therapeutic effect in treating β-thalassemia. Gene analysis revealed that it did not change the genetic mutation type

but could obviously increase hemoglobin

fetal hemoglobin (HbF)

γ/(β+γ) globin ratio

γ-globin mRNA expression and GM-CSF mRNA expression in patients

as well as the GM-CSFmRMA in marrow of mice after60Co radiation.Conclusion: YSSXL has a remarkable therapeutic effect on β-thalassemia

and its possible mechanism is its action in unlocking γ-gene

increasing the γ-globin expression and enhancing HbF synthesis so as to compensate for the gene defect. This study has opened a new path for the treatment of β-thalassemia with TCM.

Abstract

Objective: To explore the possibility of using traditional Chinese medicine (TCM) in treating β-thalassemia

its clinical effect and molecular mechanism of the action.Methods: According to the TCM theory of “Shen producing marrow”

the composite recipe

Yisui Shenxueling Granule (YSSXL)

consisting of Chinese drugs for nourishing Shen and supplementing marrow (NS & SM) was given orally to 78 patients with β-thalassemia (49 of the severe type and 29 of moderate type)

3 times a day

10 g each time (for children

the dose would be reduced properly)

with 3 months as one therapeutic course

and no blood transfusion used in the course. The clinical therapeutic efficacy and hematologic parameters in patients were observed

and systemic gene analysis was conducted with PAGE

PCR

PCR-SSCP

RT-PCR and DNA sequences analysis and mRNA detection

in order to study the molecular mechanism from the relationships between genetic mutation and clinical efficacy

gene expression and its regulation.Results: YSSXL showed obvious therapeutic effect in treating β-thalassemia. Gene analysis revealed that it did not change the genetic mutation type

but could obviously increase hemoglobin

fetal hemoglobin (HbF)

γ/(β+γ) globin ratio

γ-globin mRNA expression and GM-CSF mRNA expression in patients

as well as the GM-CSFmRMA in marrow of mice after60Co radiation.Conclusion: YSSXL has a remarkable therapeutic effect on β-thalassemia

and its possible mechanism is its action in unlocking γ-gene

increasing the γ-globin expression and enhancing HbF synthesis so as to compensate for the gene defect. This study has opened a new path for the treatment of β-thalassemia with TCM.

关键词

nourishing Shen and supplementing marrow principleShen producing marrowβ-thalassemiagene analysismRNA gene expressionmolecular mechanism

Keywords

nourishing Shen and supplementing marrow principleShen producing marrowβ-thalassemiagene analysismRNA gene expressionmolecular mechanism

references

WANG RX, HUANG YW, ZHANG XH, et al. Further clinical study of “Yisui Shengxueling” in treating β-thalassemia. Chinese Journal of Eugenic and Heredity 1998;6(2): 28–29.

WU ZK, CHEN SH, JIANG BH, et al. The clinical and mechanism study of “Zhongguo Shenfang” on treating β-thalassemia. Pharmacology and Clinicals of Chinese Materia Medica 1991; 7(5): 37–39.

ZHANG ZN. The Standard for Diagnosis and Treatment of Hematopathy. Tianjin: Tianjin Science and Technology Press, 1991: 48–49.

CAO A, Calanello R, Rosatelli MC, et al. Clinical experience of management of β-thalassemia:The Sardinian experience. Seminars in Hematolgy 1996;33(1): 70–73.

HUANG SZ, REN ZR, CHEN MY, et al. Study of hydroxyurea in treating β-thalassemia—Effect of hydroxyurea on globin expression. Chinese Science (B volume) 1994;22(2): 171–174.

LIU DP, LIANG ZQ, AO ZH, et al. Myleran can increase synthesis of hemoglobin in fetal of rhesus monkey. J China Academy of Medical Science 1986; 8: 419–421.

LIU DP, LIANG ZQ, AO ZH, et al. Treatment of severe β-thalassemia (patient) with Myleran. American Journal of Hematology 1990;33: 50–52.

FULL TEXT LINK

More>

Views

357

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Study on the effect of Youguiyin (右归饮) on regulating gene expression profile of the rats with femoral head necrosis induced by steroid

Study on molecular mechanism of liver yang ascending syndrome in hypertension

Related Author

No data

Related Institution

Zhejiang Traditional Chinese Medicine University

Zhejiang Provincial Institute of Ortopaedics and Traumatology

Ortopaedics and Traumatology Department of Zhejiang Provincial Traditional Chiese Medicine Hospital, the First Affiliated Hospital of Zhejiang Traditional Chinese Medicine University

Institute of Integrated Traditional Chinese and Western Medicine, The Affiliated Xiangya Hospital, Hunan Medical University

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰